Odyssey Therapeutics, Inc. Common Stock (ODTX) - Total Liabilities
Based on the latest financial reports, Odyssey Therapeutics, Inc. Common Stock (ODTX) has total liabilities worth $62.63 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Odyssey Therapeutics, Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Odyssey Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Odyssey Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check ODTX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Odyssey Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Odyssey Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
USA | $7.55 Billion |
|
Creades AB
ST:CRED-A
|
Sweden | Skr39.00 Million |
|
Plazza AG
SW:PLAN
|
Switzerland | CHF555.12 Million |
|
KBC Corporation Ltd
SHG:688598
|
China | CN¥1.31 Billion |
|
Guanghui Logistics Co Ltd
SHG:600603
|
China | CN¥13.16 Billion |
|
Hangzhou Weiguang Electronic Co Ltd
SHE:002801
|
China | CN¥490.78 Million |
|
Simply Good Foods Co
NASDAQ:SMPL
|
USA | $644.32 Million |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
China | CN¥275.13 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Odyssey Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ODTX current and non-current assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Odyssey Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Odyssey Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Odyssey Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $758.07 Million | +30.71% |
| 2024-12-31 | $579.96 Million | +5.60% |
| 2023-12-31 | $549.23 Million | +18.94% |
| 2022-12-31 | $461.77 Million | -- |
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated … Read more